Canntab Nears Commercialization with Innovative Cannabis Tablets
Ryan Allway
December 3rd, 2018
Exclusive, News, Top News, Top Story
The global cannabis industry is projected to reach $146.4 billion by 2025, according to Grand View Research, representing a blistering 34.6 percent compound annual growth rate. With medical and adult-use legalization across a growing number of countries, there’s an enormous opportunity for innovative companies to become established market leaders and patients to access new life-changing medications.
A key problem facing the medical cannabis industry is dosing and consistency. Unlike pharmaceuticals, medical cannabis is typically prescribed in a smokable form that can produce inconsistent effects between patients. Many pharmaceuticals also offer extended release and features that can make the medicine more efficacious.
Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable, for physicians and their patients benefit. Investors may want to take a closer look at the company given its robust product portfolio and growing distribution network.
Strong Product Portfolio
Canntab has made tremendous progress building an intellectual property portfolio with 13 patents pending in the United States and Canada related to its formulations of cannabis tablets, including instant release, extended release, flash melt, and bi-layer products available in 2.5mg, 5mg, and 10mg tablets. These products will address a key shortcoming in cannabis-based medications—a lack of precise, dose-controlled formats supported by pharmacokinetic, dosing, and clinical data to ensure safety and efficacy.
Last year, the company announced an exclusive agreement with Emblem Corp. (TSX-V: EMC) to develop cannabis-based oral sustained release formulations. The partnership received Health Canada’s approval for research and development activities, and dissolution testing showed that the extended release tablets delivered cannabinoids consistently over a 12-hour period. The team plans to file dossiers with regulatory agencies around the world.
In addition to these agreements, Health Canada recently approved the company’s 420 Therapeutics brand of cannabis wellness capsules that are made from purified organic hemp seed oil. These capsules are an easy and convenient way to realize the health benefits of hemp oil, while setting the stage for the company’s long-term goal of manufacturing full spectrum hemp-derived cannabidiol (CBD) oil.
Joint Venture Distribution
Canntab has signed a number of joint venture agreements around the world to distribute its products to patients across many jurisdictions.
The company announced a non-binding letter of intent with NewCanna SAS of Bogota, Colombia to establish a significant bilateral relationship for the sale and distribution of its products. Under the agreement, NewCanna will distribute products across Colombia, Chile, Paraguay, and Spain in exchange for a one-time, non-refundable license fee of $2 million payable to Canntab after the agreement is finalized.
More recently, the company announced a non-binding letter of intent with Labsco Promedic SA of Monterrey, Mexico to establish a new distribution channel in Mexico. Under the terms of the agreement, the companies will work together to formalize a joint venture before the end of the year and launch products within the next five years. Mexico could become a significant market given the government’s recent liberalization of cannabis laws.
Looking Ahead
Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) is rapidly approaching commercialization with new distribution channels in place. In addition, the company recently filed an application to become a licensed producer under Health Canada’s ACMPR program. If approved, the new designation would enable the company to manufacture products at its current production facility with minimal additional capital expenditure as compared to a new purpose-built facility.
With an excellent cap structure and no need for short-term financing, investors may want to take a closer look at the company as it gears up for commercialization. The potential approval of its tablets and new license from Health Canada could prove to be significant catalysts, while new joint venture agreements could pave the way to near-term income.
For more information, visit the company’s website at www.canntab.ca.
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
DNA Genetics has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation.
Xphyto Therapeutics Corp. was created to bridge the gap between traditional cannabis-based medicine and modern scientific approaches to therapeutic validation.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
